Cancer Research UK, Cytovation and the Norwegian Cancer Society have signed an agreement to bring Cytovation’s lead asset, CY-101, into a multi-national Phase II clinical trial for patients with adrenocortical carcinoma (ACC). CY-101, developed by Cytovation, is a synthetic peptide with a dual function. It selectively targets and destroys cancer cells, triggering a systemic immune […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!